
Sign up to save your podcasts
Or
Professor Margaret Ragni joins us to discuss the VWDMin study, published in The Lancet Haematology. In this phase 3, randomised, crossover trial, recombinant von Willebrand factor and tranexamic acid are used to treat heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA.
Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00119-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Professor Margaret Ragni joins us to discuss the VWDMin study, published in The Lancet Haematology. In this phase 3, randomised, crossover trial, recombinant von Willebrand factor and tranexamic acid are used to treat heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA.
Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00119-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
11,418 Listeners
22 Listeners
0 Listeners
0 Listeners
2 Listeners
1 Listeners
0 Listeners
1 Listeners
0 Listeners
0 Listeners
2 Listeners
0 Listeners
0 Listeners
2 Listeners
0 Listeners
0 Listeners
0 Listeners
0 Listeners
1 Listeners
0 Listeners
0 Listeners